Advertisement


Oleg Gluz, MD, on Response to Endocrine Therapy: Findings From the ADAPTcycle Trial

2023 SABCS

Advertisement

Oleg Gluz, MD, of the West German Study Group and Breast Center Niederrhein, discusses the impact of age and ovarian function suppression in response to preoperative endocrine treatment for both pre- and postmenopausal patients with early-stage breast cancer. He describes ways in which the outcome data of the ADAPTcycle study might influence clinical decisions (Abstract LBO1-05).



Related Videos

Breast Cancer

Cynthia X. Ma, MD, PhD, on Metastatic Breast Cancer: Early Results on Copanlisib, Fulvestrant, and Abemaciclib

Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, discusses phase I findings showing the safety and tolerability of copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer. Preliminary antitumor activity, which was observed, will be further examined in the phase II trial (ClinicalTrials.gov identifier NCT03939897) (Abstract PS17-06).

Breast Cancer

Sara A. Hurvitz, MD, on Metastatic Breast Cancer: New Data on Tucatinib and Trastuzumab Emtansine

Sara A. Hurvitz, MD, of Fred Hutchinson Cancer Research Center, University of Washington, discusses phase III findings of the HER2CLIMB-02 study, which showed the combination of tucatinib and trastuzumab emtansine improved progression-free survival in patients with previously treated, HER2-positive, locally advanced or metastatic breast cancer (including those with brain metastases) (Abstract GS01-10).

Breast Cancer

Aditya Bardia, MD, MPH, on Early-Stage, High-Risk Breast Cancer: New Data on Pembrolizumab Plus Chemotherapy

Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses phase III findings from the KEYNOTE-756 study, which showed that adding pembrolizumab to chemotherapy increases the pathologic complete response rate and lowers the residual cancer burden in patients with early-stage, high-risk ER-positive or HER2-negative breast cancer (Abstract GS01-02).

Breast Cancer

Hope S. Rugo, MD, on Triple-Negative Breast Cancer: Trial Update on Pembrolizumab Plus Olaparib vs Pembrolizumab Plus Chemotherapy

Hope S. Rugo, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses data from the phase II KEYLYNK-009 study, which compared pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (Abstract GS01-05).

Breast Cancer

Gabriel N. Hortobagyi, MD, on Early Breast Cancer: Final Invasive Disease–Free Analysis From the NATALEE Trial

Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the NATALEE trial, which continued to demonstrate improved invasive disease–free survival with ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) over a NSAI alone in patients with hormone receptor–positive, HER2-negative early breast cancer (Abstract GS03-03).

Advertisement

Advertisement




Advertisement